Regen BioPharma, Inc.
RGBP
$0.058
-$0.0034-5.54%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -0.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -0.51% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | -0.51% | |||
| SG&A Expenses | 43.19% | 7.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.19% | -17.36% | |||
| Operating Income | -84.53% | 28.94% | |||
| Income Before Tax | 96.24% | -94.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 96.24% | -94.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 96.24% | -94.56% | |||
| EBIT | -84.53% | 28.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 99.28% | -327.99% | |||
| Normalized Basic EPS | 99.23% | -328.42% | |||
| EPS Diluted | 99.28% | -327.99% | |||
| Normalized Diluted EPS | 99.23% | -328.42% | |||
| Average Basic Shares Outstanding | 424.41% | -54.51% | |||
| Average Diluted Shares Outstanding | 424.41% | -54.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||